Leaderboards/Myeloproliferative Neoplasms: Diagnosis and Treatment

Myeloproliferative Neoplasms: Diagnosis and Treatment

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Caitlyn Vlasschaert
Queen's University
2
Abhishek Niroula
Broad Institute
3
Álex Bataller
The University of Texas MD Anderson Cancer Center
4
Niels Asger Jakobsen
University of Oxford
5
Caleb R. Glassman
Stanford University
6
Yanis Tazi
Memorial Sloan Kettering Cancer Center
7
Miriam Díez-Díez
Spanish National Centre for Cardiovascular Research
8
Joshua S. Weinstock
University of Michigan
9
Evan Cherry
Unknown
10
Wan‐Hsuan Lee
National Taiwan University Hospital

Papers

1
Publication in Cell stem cell (2024) [98 citations, W4399970144]
Cell stem cell|2024
98 cit.
2
Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury
Nature Medicine|2024
75 cit.
3
Unidirectional association of clonal hematopoiesis with atherosclerosis development
Nature Medicine|2024
72 cit.
4
Publication in Blood Cancer Journal (2024) [26 citations, W4394613085]
Blood Cancer Journal|2024
26 cit.
5
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
The Lancet Haematology|2024
23 cit.
6
Clonal Hematopoiesis of Indeterminate Potential and Progression of CKD
Journal of the American Society of Nephrology|2025
16 cit.
7
Gene regulatory network inference from CRISPR perturbations in primary CD4+ T cells elucidates the genomic basis of immune disease
Cell Genomics|2024
13 cit.
8
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
Haematologica|2024
12 cit.
9
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study
Blood Cancer Journal|2025
10 cit.
10
Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
Blood|2024
8 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Pedro M. Quirós
Universidad de Oviedo
2
Rob S. Sellar
University College London
3
James P. Pirruccello
University of California, San Francisco
4
Alan H. Shih
Tisch Hospital
5
Alexander G. Bick
Vanderbilt University Medical Center
6
Jyoti Nangalia
Wellcome Sanger Institute
7
Yan‐Zeng Jia
Eisai (United States)
8
José J. Fuster
Spanish National Centre for Cardiovascular Research
9
Isidro Cortés‐Ciriano
European Bioinformatics Institute
10
Alica Joana Emhardt
LMU Klinikum

Papers

1
Life histories of myeloproliferative neoplasms inferred from phylogenies.
RePEc: Research Papers in Economics|2022
231 cit.
2
A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets
Blood|2023
140 cit.
3
De novo detection of somatic mutations in high-throughput single-cell profiling data sets
Nature Biotechnology|2023
101 cit.
4
Genetic analysis of right heart structure and function in 40,000 people
Nature Genetics|2022
98 cit.
5
Clonal hematopoiesis in cardiovascular disease and therapeutic implications
Nature Cardiovascular Research|2022
97 cit.
6
Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA
Cancer Discovery|2023
90 cit.
7
Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis
Nature Genetics|2024
85 cit.
8
Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury
Nature Medicine|2024
75 cit.
9
Colchicine prevents accelerated atherosclerosis in <i>TET2</i>-mutant clonal haematopoiesis
European Heart Journal|2024
73 cit.
10
Unidirectional association of clonal hematopoiesis with atherosclerosis development
Nature Medicine|2024
72 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Ayalew Tefferi
Mayo Clinic
2
Tiziano Barbui
University of Bergamo
3
Anthony R. Green
Wellcome/MRC Cambridge Stem Cell Institute
4
Srđan Verstovšek
Unknown
5
Ross L. Levine
Memorial Sloan Kettering Cancer Center
6
Alessandro M. Vannucchi
Azienda Ospedaliero-Universitaria Careggi
7
Radek C. Skoda
University Hospital of Basel
8
Benjamin L. Ebert
Dana-Farber Cancer Institute
9
Hagop M. Kantarjian
The University of Texas MD Anderson Cancer Center
10
William Vainchenker
Inserm

Papers

1
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
New England Journal of Medicine|2014
4.7k cit.
2
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
Nature|2005
3.5k cit.
3
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
New England Journal of Medicine|2005
3.5k cit.
4
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
The Lancet|2005
3.4k cit.
5
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Cancer Cell|2005
3k cit.
6
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood|2022
2.7k cit.
7
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
New England Journal of Medicine|2017
2.6k cit.
8
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
New England Journal of Medicine|2012
2k cit.
9
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
New England Journal of Medicine|2012
1.9k cit.
10
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Blood|2015
1.9k cit.

Reagents for Myeloproliferative Neoplasms: Diagnosis and Treatment

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 67

Stat5 (D2O6Y) Rabbit Monoclonal Antibody

Cited in 9 papers
#94205$152,844
View Evidence →
Cell Signaling TechnologyEvidence 64

ATP2A1/SERCA1 (A988) Antibody

Cited in 9 papers
#4274$317
View Evidence →
Cell Signaling TechnologyEvidence 65

Bim (C34C5) Rabbit Monoclonal Antibody (Alexa Fluor® 488 Conjugate)

Cited in 8 papers
#94805$465
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Ermin (F4O7S) Rabbit Monoclonal Antibody

Cited in 23 papers
#18962$161,376
View Evidence →
Cell Signaling Technology

PathScan® Phospho-Chk2 (Thr68) Sandwich ELISA Kit

Cited in 11 papers
#7037$66,129,740
View Evidence →
Cell Signaling TechnologyEvidence 65

Phospho-Tyrosine Mouse Monoclonal Antibody (P-Tyr-100) (Alexa Fluor® 488 Conjugate)

Cited in 11 papers
#9414$493
View Evidence →